Molecular Biomarkers & Diagnosis

ISSN: 2155-9929

Open Access

Current Issue

Volume 11, Issue 4 (2020)

    Editorial Pages: 1 - 1

    miRNA as Potential Biomarkers for Cardiomyopathy

    Pritun Pradhan

    DOI: 10.37421/jmbd.2020.11.428

    Heart failure implies that the heart works less effectively and not that the heart has quit working. Heart failure is caused by many conditions that damage the heart muscle. Coronary artery disease is where the arteries minimises the supply of oxygen and blood flow to the heart muscle. When the heart muscles are damaged from infections or alcohol or drug abuse rather than the minimal supply of oxygen or blood, is known as Cardiomyopathy.

    Editorial Pages: 1 - 1

    DNA Profiling in Identification of Mutational Signatures

    Pritisnigdha Pattnaik

    DOI: 10.37421/jmbd.2020.11.429

    Cancer is designated as unhindered cell growth. Gene mutations can initiatemalignancy by increasing the rate of cell division or preventing usual controls on the system, like cell cycle arrest or apoptosis. As per earlier established studies, it is well known that the primary cause of cancer is some unwanted changes in the structure of DNA that are else considered as mutations. Mutations causing cancer can be due to a number of reasons including the lack of fidelity of the DNA replication machinery, disclosures to the mutagen, enzymatic DNA alteration, and faulty repair of DNA that consequences a certain fingerprint on DNA damage. Every living cell of the human body retains somatic mutations all through life. 

    Editorial Pages: 1 - 1

    Application of Biomarkers in Cancer Diagnosis and Treatment

    Debasish Mohapatra

    DOI: 10.37421/jmbd.2020.11.430

    The Biomarker is “a biological molecule contained in blood, other body fluids, or tissues, a sign of a normal or abnormal process, or of a disorder or disease," like cancer as described by the National Cancer Institute (NCI). Usually biomarkers differentiate the healthy person from the patient with disease. The modifications may be caused by many factors, such as germ or somatic mutations, transcriptional changes, and post-translational changes. The spectrum of biomarkers is vast, including proteins (for instance, an enzyme or receptor), nucleic acids (e.g. micro-RNA or other non-encoding ARNs), antibodies and peptides, etc. A biomarker may also be a series of changes such as gene expression, proteomic signatures and metabolomics. Biomarker can be found in the bloodstream or excretions (stool, urine, sputum or nipple discharge) (wholly blood, serum, or plasma). 

    Editorial Pages: 1 - 2

    Development and Application of Molecular Markers: Past and Future

    Shalini Pal

    DOI: 10.37421/jmbd.2020.11.431

    Biomarkers are regarded highly for their ability to discriminate between genotypes in fields of genetic science. The first molecules to differentiate between various plant types were secondary metabolites such as anthocyanin, phenolic etc. Nevertheless, their wide use was restricted by several factors including uncertainty and limited availability. For the short period prior to the development of more effective DNA markers, enzyme markers (allozymes and isozymes) gained significance but with the development of the powerful DNA markers that detect variation among individuals based on the polymorphism in their DNA they regained their status. Initial application of DNA marker technology began with the use of RFLP markers for the creation of the human genome's first molecular map.

    Case Report Pages: 1 - 6

    Serum miR-92a is Elevated in Children and Adults with Obstructive Sleep Apnea

    Brendan Gongol, Fenqing Shang, Yingshuai Zhao, Weili Shi, Manli Cheng, John YJ. Shyy, Liuyi Wang, Atul Malhotra and Rakesh Bhattacharjee

    DOI: 10.37421/jmbd.2020.11.426

    Background: Obstructive Sleep Apnea (OSA) is a highly prevalent condition that is associated with several comorbidities including cardiovascular disease (CVD). Recent studies have revealed mixed results as to whether standard OSA therapy reverses CVD in adult patients. Thus, many advocate for earlier recognition of OSA induced CVD, as early as childhood, to prompt treatment antecedent to the onset of irreversible CVD. Here we investigated if the serum level of miR-92a, a known biomarker for CVD, can be used to identify patients with OSA in both children and adults. Methods: Consecutive snoring patients undergoing polysomnography were recruited for determination of circulating miR-92a, in addition to inflammatory and metabolic profiles. We assessed whether circulating miR-92a was associated with OSA severity. Results: Using two separate cohorts of adults (n=57) and children (n=13), we report a significant increase in the serum level of miR-92a in patients with severe OSA (p=0.021) and further demonstrate a significant correlation (Spearman rank correlation 0.308, p=0.010) with serum miR-92a levels and the apnea hypopnea index (AHI), a primary measure of OSA severity. Stepwise regression analysis revealed that serum miR-92a levels were independently associated with AHI (ß=0.332, p=0.003), age (ß=0.394, p=0.002) and LDL cholesterol levels (ß=0.368, p=0.004). Conclusion: Our study is the first to establish that miR-92a is a useful biomarker for OSA severity in both children and adults. Given the canonical role of miR-92a on endothelial dysfunction, miR-92a may be useful to identify early onset CVD in OSA patients or stratify patient CVD risk to identify those that may benefit from earlier OSA treatment. 

    Editorial Pages: 1 - 1

    Biomarkers in Early Detection of Oral Cancer

    Bedadyuti Mohanty

    DOI: 10.37421/jmbd.2020.11.427

    Prevention and early detection are key components of controlling the overburdened cases of mouth cancer. Mouth cancers are the 6th commonest cancer in the world with a high lethality rate. Even with technological advances happening around the globe, visual examination still remains the mostly practiced screening method for oral cancer. 

    Volume 11, Issue 5 (2020)

      Editorial Pages: 1 - 1

      The Significance of Biomarkers

      Subhadra Rani Jena

      DOI: 10.37421/jmbd.2020.11.432

      The term “biomarker” can be described as biochemical, molecular, or cellular modifications that are detectable in organic media such as human cells, tissues, or fluids. Biomarkers comprise tools that can assist in predicting the root, diagnosis, succession, and effect of treatment of disease. Biomarkers can also mirror the complete range of ailment as of the initial appearances to the fatal stages. 

      Editorial Pages: 1 - 1

      Development of Non-Invasive Biomarkers for Diagnostic and Monitoring of Cancer

      Debasish Mohapatra

      DOI: 10.37421/jmbd.2020.11.433

      Common cancers are currently being identified on a wide scale technique for screening such as CT scans for lung cancer, breast cancer mammograms, and ovarian ultrasounds. While advancement in imaging technology has made identification of small lesions more effective, these improvements have led to an increase in false positives and invasive procedures for definitive diagnosis. 

      Editorial Pages: 1 - 1

      Biomarkers in Identification of COVID-19

      Pritisnigdha Pattnaik

      DOI: 10.37421/jmbd.2020.11.434

      Wuhan, the most populous city of central China, developed a mysterious circumstance of pneumonia on December 2019, a series of acute respiratory illnesses were reported. The scientists of China recognized this as a novel coronavirus on January 2020. On February 2020, the coronavirus disease spread globally. People infected with SARS-CoV-2, the cause ofCOVID-19, react contrarily. Some patients were asymptomatic, some require to be hospitalized and, for some, the disease became lethal. Hence, it is vital to establish a patient's state in an appropriate method. Biomarkers are quantitative measurements used clinically for many conditions reflecting pathological development.

      Editorial Pages: 1 - 1

      microRNAs as a Novel Biomarker for Diagnosis of Diabetes Mellitus

      Shalini Pal

      DOI: 10.37421/jmbd.2020.11.435

      Diagnosis of diabetes mellitus, according to the World Health Organization, is based on blood glucose levels in the fasted condition and the oral glucose tolerance test. Glucose levels above 7.0 mmol/L (126 mg/dl) in the fast state are known as diabetes and after an oral glucose tolerance test is above 11.1 mmol/L (200 mg/dl). Other serum parameters such as residual C-peptide or serum parameters such as glycated haemoglobin (HbA1c) may also help to diagnose diabetes mellitus.

      Editorial Pages: 1 - 1

      Tumour Necrosis Factor-? as a Biomarker in Oral Leukoplakia and Oral Squamous Cell Carcinoma

      Bedadyuti Mohanty

      DOI: 10.37421/jmbd.2020.11.436

      Oral cavity squamous cell carcinoma (OSCC) are 95% contributor of all oral cavity carcinomas around the world.  Though the malignancy is prevalent, especially in developing, the attention regarding the diagnosis or treatment has not been satisfactory when compared to other malignancies like lung, breast, or colon cancer.

    Relevant Topics

Recommended Conferences

Antibiotics: Discovery & Development

New York, USA

World Biotechlogy Congress 2020

Barcelona, Spain


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward